| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1249 |
| Trial ID | NCT00306904 |
| Disease | Diabetic Macular Edema |
| Altered gene | VEGF |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | Cand5|bevasiranib |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Diabetic Macular Edema |
| Year | 2006 |
| Country | United States |
| Company sponsor | OPKO Health, Inc. |
| Other ID(s) | ACU211 |
| Cohort1: bevasiranib_dose level 1 | |||||||||
|
|||||||||
| Cohort2: bevasiranib_dose level 2 | |||||||||
|
|||||||||
| Cohort3: bevasiranib_dose level 3 | |||||||||
|
|||||||||